Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease

Current Opinion in Neurology

Volumn 16, Issue SUPPL. 1, 2003, Pages

  Hattori, Nobutaka ^a,b  

^a JUNTENDO UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Dopamine agonist; Optimal dose; Pergolide

Indexed keywords

BROMOCRIPTINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; PERGOLIDE;

AUTONOMIC DYSFUNCTION; BRADYKINESIA; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; GAIT; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; JAPAN; LONG TERM CARE; PARKINSON DISEASE; RIGIDITY; SIDE EFFECT;

EID: 1542267700     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200312001-00005     Document Type: Conference Paper

References (32)

1. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988; 24:366-371.
2. Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
3. Fahn S: "On-off" phenomenon with levodopa therapy in parkinsonism. Neurology 1974; 24:431-441.
4. Obeso JA, Rodriguez-Orez MC, Chana P, et al. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000; 55 (Suppl 4):S13-S20.
5. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53:573-579.
6. Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C, et al. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. Clin Neuropharmacol 1998; 21:358-362.
7. Oertel WH, Schwarz J, Leenders KL, et al. on behalf of the Pelmopet-Study Group. Results of a 3 year randomized, double-blind, PET-controlled study of Pergolide vs. L-dopa as Monotherapy in Early Parkinson's Disease (PELMOPET-trial). J Neurol Sci 2001; 187 (Suppl 1):S444.
8. Olanow CW, Alberts MJ. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease. Clin Neuropharmacol 1987; 10:178-185.
9. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994; 9:40-47.
10. Boas J, Worm-Peterson J, Dupont E, et al. The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label crossover study. Eur J Neurol 1996; 3:44-49.
11. Ahlskog JE, Muenter MD. Treatment of Parkinson's disease with pergolide: a double-blind study. Mayo Clin Proc 1988; 63:969-978.
12. Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol 1986; 45:551-554.
13. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9:431-436.
14. Goetz CG, Tanner CM, Glantz RH, et al. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35:749-751.
15. Lieberman AN, Neophytides A, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 1983; 37:95-108.
16. Tuite P, Ebbitt B. Dopamine agonists. Semin Neurol 2001; 21:9-14.
17. Lledo A, Hundemer HP, van Laar T, et al. Long-term efficacy of pergolide monotherapy in early-stage Parkinson's disease. One-year interim analysis of a 3-year double-blind, randomized study versus levodopa [abstract]. Mov Disord 2000; 15:126.
18. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995, 45 (Suppl 3):S13-S21.
19. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS0009 Study Group. Drugs 1998; 55:23-30.
20. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342:1484-1491.
21. The Pramipexole Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 2000; 284:1931-1938.
22. Bonuccelli U, Colzi A, Del Dotto P. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin Neuropharmacol 2002; 25:1-10.
23. Schwarz J, Scheidtmann K, Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment of pergolide and cessation of levodopa. Eur Neurol 1997; 37:236-238.
24. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996; 11:327-329.
25. Lieberman A, Goldstein M, Leibowitz M, et al. Treatment of advanced Parkinson's disease with pergolide. Neurology 1981; 31:675-682.
26. Tanner CM, Goetz CG, Glantz RH, et al. Pergolide mesylate and idiopathic Parkinson's disease. Neurology 1982; 32:1175-1179.
27. Sage JL, Duvoisin RC. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 1985; 8:260-265.
28. Grimes JD, Hassan MN, Sitwell LD, et al. Pergolide in the management of advanced Parkinson's disease. Can J Neurol Sci 1985; 12:173.
29. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985; 35:291-295.
30. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology 1985; 35:296-299.
31. Shulman LM. How to succeed in using dopamine agonists in Parkinson's disease. Eur J Neurol 2000; 7 (Suppl 1):9-13.
32. Trenkwalder C, Winkelmann J, Hundemer HP, et al. High-dose treatment of Parkinson's disease with pergolide [abstract]. Mov Disord 2000; 15 (Suppl 3):132.